Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 11th 2016

Why You Should Attend Patient-Centered Oncology Care in Baltimore

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.

October 10th 2016

COST: A New Tool to Measure Financial Toxicity as a PRO

Surabhi Dangi-Garimella, PhD

Researchers at the University of Chicago have developed a clinically relevant patient-centered tool that can measure a patient’s risk for financial stress.

October 10th 2016

Estimating the Social Value of G-CSF Therapies in the United States

Jacqueline Vanderpuye-Orgle, PhD Alison Sexton Ward, PhD Caroline Huber, MPH Chelsey Kamson, BS Anupam B. Jena, MD, PhD

Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 7th 2016

Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis has found that longer term adjuvant treatment with tamoxifen significantly decreases the risk of contralateral breast cancer.

October 7th 2016

This Week in Managed Care: October 7, 2016

This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.

October 7th 2016

Will HHS Have the Assurance of a Patient Identifier?

Surabhi Dangi-Garimella, PhD

HHS has been banned from using a patient identifier but several organizations, including national payers, providers, and prescription drug networks, want this reversed.

October 6th 2016

State-Level Insurance Reform Improved Access for Patients With CRC in Massachusetts

Surabhi Dangi-Garimella, PhD

A study published in the Journal of Clinical Oncology found an increased rate of resection and a reduction in the probability of emergent resection for colorectal cancer (CRC) as a result of insurance expansion in Massachusetts.

October 5th 2016

COA Report Accentuates Economic Strain on Community Practices

Surabhi Dangi-Garimella, PhD

According to the 2016 Community Oncology Practice Impact Report, about 15 community practices in the United States have either closed or were acquired, each month since 2008.

October 5th 2016

Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).

October 4th 2016

The Power of an Immuno-oncology Collaborative Care Team

Surabhi Dangi-Garimella, PhD

At the Institute for Clinical Immuno-Oncology National Conference, a panel of care providers presented institutional experiences with immunotherapy, and how a collaborative care approach helped the process.

October 4th 2016

PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care

Surabhi Dangi-Garimella, PhD

Precision Promise, the Pancreatic Cancer Action Network (PanCAN)'s precision medicine trial, seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020.

October 4th 2016

Specialty Pharmaceutical Pipeline: Increased Competition, Biosimilar Uncertainty

Laura Joszt, MA

Perennial favorite, Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapeutics at Express Scripts, opened the Academy of Managed Care Pharmacy 2016 Nexus, October 3, 2016, in National Harbor, Maryland, with a discussion of specialty pharmaceutical drugs in the pipeline.

October 4th 2016

Daniel J. Klein Highlights the Financial Assistance PAN Provides Patients

The funds that the Patient Access Network (PAN) Foundation provides to patients are often used to help with the cost of medications, and there has been a large increase in the number of patients looking for assistance for the cost of cancer treatments, explained Daniel J. Klein, president and CEO of the PAN Foundation.

October 3rd 2016

Knowledge Is Power for Cancer Patients, British Study Says

Christina Mattina

A study suggests that regions of England where patients show less awareness of cancer symptoms tend to have lower cancer survival rates, particularly in lower-income areas. The research, published in the British Journal of Cancer also examined whether barriers to care can affect the likelihood of surviving different cancers.

October 3rd 2016

Remarkable Outcomes With Cancer Immunotherapy, but Clinical Adoption Remains Challenging

Surabhi Dangi-Garimella, PhD

The cancer community has seen tremendous progress in the field of immunotherapy. However, educating patients and care providers across healthcare on this new tool remains a significant challenge.

October 1st 2016

This Week in Managed Care: October 1, 2016

This week, the top stories in managed care included 2 reports on the fight against addiction, researchers have learned more about the effects of healthy living on avoiding cancers, and a study finds fitness trackers do not help people lose more weight.

September 30th 2016

Sentinel Lymph Node Biopsy: Part of Melanoma Treatment's Exciting Future

Timothy M. Johnson, MD, spoke enthusiastically about the possibilities of sentinel lymph node biopsy in his lecture at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria. His presentation, called “Melanoma Sentinel Node Biopsy: Past, Present and Future in the New Era of Systemic Therapies,” covered guidelines for the procedure as well as new possibilities for melanoma patients.

September 30th 2016

ICER Recommends Significant Discount on WAC for Checkpoint Inhibitors in NSCLC

Surabhi Dangi-Garimella, PhD

Based on ICER’s evaluation, a significant reduction in the wholesale acquisition cost (WAC) of approved checkpoint inhibitors would be necessary to achieve a pre-determined value-based price benchmark.

September 30th 2016

New Anticancer Drugs Associated With Big Increases in Costs, but Also Life Expectancy

Jackie Syrop

While there have been large increases in the cost of new cancer treatments for patients with metastatic breast, lung, or kidney cancer, or chronic myeloid leukemia, researchers found that there were also large gains in life expectancy.

September 30th 2016

Dr Mario E. Lacouture on Maintaining Quality of Life While Treating Melanomas

Patients with melanoma have more promising options than ever with the advent of targeted therapies and immunotherapies, said Mario Lacouture, MD, director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center. His research aims to provide patients the best possible quality of life while taking these treatments, which can often have adverse effects.

September 29th 2016

Preventive Oophorectomy Contraindicated in Women With an Average Risk of Ovarian Cancer

Surabhi Dangi-Garimella, PhD

Researchers at the Mayo Clinic are recommending that premenopausal women with a low risk of ovarian cancer should be spared unnecessary comorbidities associated with bilateral oophorectomy.

September 29th 2016

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study

Surabhi Dangi-Garimella, PhD

A new study has found that after adjusting for changes in screening, there was a decrease in incidence of all grades of cervical intraepithelial neoplasia (CIN) for women 15- to 19-years old, and CIN grade 2 in women 20- to 24-years old.

September 28th 2016

USPSTF Recommendation Did Not Impact PSA Testing Referrals, Study Finds

Surabhi Dangi-Garimella, PhD

A study published in the journal Cancer has discovered that a 2012 recommendation for prostate cancer screening did not change physician behavior.

September 28th 2016

Dr Ally-Khan Somani: Mohs Surgery Is a Gold Standard

Mohs surgery is generally the gold standard for rare and more aggressive tumors because the surgeon can ensure the roots of the tumor are gone, but the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.

September 28th 2016

Dr Aleksandar Krunic Discusses the Reimbursement Issues of Mohs Surgery

Reimbursement issues surrounding Mohs surgery are getting worse, which provides a challenge for surgeons who would perform the procedure, explained Aleksandar L. Krunic, MD, PhD, during the 25th European Academy of Dermatology and Venereology Congress.

September 28th 2016

Chemotherapy and RT Improve Survival in Surgically Resected Medulloblastoma Patients

Surabhi Dangi-Garimella, PhD

A new study presented at the annual meeting of the American Society for Radiation Oncology has found a significant survival advantage of combining chemotherapy and radiotherapy following surgery in patients with medulloblastoma.

September 27th 2016

SBRT Improves Outcomes in Older NSCLC Patients With Stage I Disease

Surabhi Dangi-Garimella, PhD

Use of stereotactic body radiation therapy improved survival in elderly patients diagnosed with early-stage non-small cell lung cancer by about 20% over a decade.

September 27th 2016

The Big "C" — Is Cancer Curable?

Advancement in basic science and medical technology has made cancer a curable disease for many patients. Approximately 40% of Americans will be diagnosed with cancer in their lifetime, but as of 2014, 1 in 22 Americans is a cancer survivor, which equals 14.5 million cancer survivors in the US, explained Joseph C. Alvarnas, MD, director of value-based analytics for the City of Hope.

September 27th 2016

The Patient Lens on Precision Medicine

Jack Whelan, an e-patient advocate and patient with a rare blood disease, spoke at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. In his presentation, Whelan explained that patient centricity and education is important for all parties in the healthcare industry to better take hold of.

...

92 93 94 95 96 97 98 99 100

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions